Roche combo of breast cancer drugs shows modest benefit

CHICAGO (Reuters) - A clinical trial from Roche Holding AG combining the company's newer targeted drug for breast cancer with an older treatment resulted in a modest benefit for women with a specific type of disease, according to data presented on Monday.